Skip to content
aTyr Pharma logo — aTyr is a biotherapeutics company engaged in the development...

aTyr Pharma

aTyr is a biotherapeutics company engaged in the development of innovative medicines based on novel biology.

Founded 2005 United States San Diego, United States 79 employees Post-IPO Equity Total: $402.50M Biotechnology, Health and Wellness +1

General Information

Company Name aTyr Pharma
Founded Year 2005
Location United States San Diego, United States
Founders / Decision Makers
Team member Team member
Employees 79
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with aTyr Pharma. To contact aTyr Pharma, visit atyrpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does aTyr Pharma compare?

A PDF of aTyr Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting aTyr Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About aTyr Pharma

aTyr Pharma is a biotherapeutics company that is focused on developing innovative medicines based on novel biology. The company, listed on Nasdaq under the symbol LIFE, is dedicated to the discovery and development of medicines based on novel biological pathways, particularly the extracellular functionality and signaling pathways of tRNA synthetases. With a robust global intellectual property estate, aTyr Pharma has directed its efforts towards a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. The company's primary focus is on their clinical-stage product candidate efzofitimod (ATYR1923), designed to bind to the neuropilin-2 receptor and down-regulate immune engagement in severe inflammatory lung diseases. The company was founded in 2005 by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., who are leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. In a recent development, aTyr Pharma secured a $50.00M Post-IPO Equity investment on 08 February 2023. For more information about the company, please visit http://www.atyrpharma.com. With its innovative approach to drug development, aTyr Pharma presents an exciting opportunity for investors looking to be part of cutting-edge advancements in the biotechnology and pharmaceutical industries.

Business keywords: Biotherapeutics, Drug discovery, Biologics, Immunomodulation, Rare diseases, Orphan diseases, Autoimmune diseases, Protein biologics, Inflammatory lung diseases, Extracellular pathways, tRNA synthetases, Neuropilin-2 receptor, Preclinical development, Intellectual property, Life sciences

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $50.00M -
08 Feb 2023
Post IPO Equity $86.30M -
15 Sep 2021
Post IPO Equity $20.70M -
10 Mar 2020
Post IPO Equity $45.00M 3
Redmile Group, EcoR1 Capital +1
28 Aug 2017
Post IPO Debt $20.00M 2
Solar capital, Silicon Valley Bank
21 Nov 2016
Series E $76.00M 10
Domain Associates, Sofinnova Investments +8
31 Mar 2015
Series D $49.00M 5
Eight Roads Ventures, Polaris Partners +3
29 Jul 2013
Debt Financing $10.00M 1
Silicon Valley Bank
29 Jul 2013
Series C $23.00M 4
Polaris Partners, Alta Partners +2
26 Oct 2010
Series C $12.00M 3
Polaris Partners, Alta Partners +1
15 Sep 2009

View All 11 Funding Rounds

aTyr Pharma Alternatives & Competitors

View All Alternatives
aTyr Pharma vs

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.

IPO
264 employees
Biotechnology, Health and Wellness
aTyr Pharma vs
Airway Therapeutics
Airway Therapeutics United States

Developing a new class of biologics for patients with respiratory and inflammatory diseases.

Series C
11 employees
Biotechnology, Health Care
aTyr Pharma vs

Changing the course of CNS disease

Series C
36 employees
Biotechnology, Health Care

FAQ About aTyr Pharma

aTyr is a biotherapeutics company engaged in the development of innovative medicines based on novel biology.
aTyr Pharma was founded in 2005.
aTyr Pharma is headquartered in San Diego, United States.
aTyr Pharma operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Biotherapeutics, Drug discovery, Biologics and Immunomodulation.
aTyr Pharma has approximately 79 employees.
aTyr Pharma has completed 11 funding rounds, raising a total of $402.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to aTyr Pharma include Zymeworks Inc., Airway Therapeutics, Evox Therapeutics Ltd, LIPUM AB, Engimmune Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
aTyr Pharma and Zymeworks Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for aTyr Pharma, https://bouncewatch.com/company/atyr-pharma, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout